Drug intelligence / Profile preview

HC103

Development stage: Preclinical
Lead developer: HebeCell
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

HC103 is an off-the-shelf, induced pluripotent stem cell (iPSC)-derived Chimeric Antigen Receptor (CAR) Natural Killer (NK) cell therapy (PSC-CAR-NK) currently in preclinical development by HebeCell. Designed for the treatment of various blood malignancies, HC103 leverages HebeCell's proprietary platform to generate a standardized and scalable source of therapeutic NK cells. These cells are engineered with a CAR to specifically recognize and eliminate malignant hematologic cells through direct cytotoxic mechanisms, offering a potential alternative to patient-specific autologous therapies.

Beyond the preview

Go deeper on HC103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC103.

Explore the full profile